logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

Seattle Genetics and Pieris Pharmaceuticals: A Collaboration to Improve Cancer Immunotherapy

Seattle Genetics and Pieris pharmaceutical Collaboration Agreement Pieris Pharmaceuticals (PIRS)  and  Seattle Genetics (SGEN)  signed a multi-program immuno-oncology collaboration agreement intended to evaluate novel bi-specific immuno-oncology agents. These agents would combine  Pieris’ Anticalin proteins drugs  with Seattle Genetics’ targeted antibodies...

Read More

February 15, 2018

0

Portola: Ignoring the Good News. Aimmune Therapeutic’s Drug AR101 Met Its Primary Efficacy Endpoint

Portola Pharmaceuticals and the CHMP’s Oral Explanations  for Andexanet Alfa and Betrixaban Portola (PTLA)   announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has communicated a  positive trend vote  on the Marketing Authorization Application (MAA)...

Read More

February 21, 2018

0

Alnylam Reaches Prohost 2018 Target. Regeneron Negotiates a Lower Price for Praluent

Alnylam (ALNY)  announced that Sanofi Genzyme declined its opt-in for the development and commercialization of the RNAi product  lumasiran , an investigational RNAi therapeutic for the treatment of  Primary Hyperoxaluria Type 1 (PH1).  Based on this decision, Alnylam intends to...

Read More

March 13, 2018

0

ObsEva Announced Positive Results from Its Product Nolasiban for In Vitro Fertilization

FERTILITY Fertility is what guarantees the presence of humans on the planet Earth. The reproductive system in men and women are the engines of fertility that creates living beings. These important engines get disturbed in some people, which represents a...

Read More

February 27, 2018

0

Regeneron’s Product Dupixant is Shown to Improve the Management of Asthma

Regeneron’s (REGN)   pipeline products have still a lot of good news to announce. The latest is about its product Dupixant (dupilumab) which has already been FDA approved for atopic dermatitis. Now, there are reasons to believe that this drug...

Read More

March 6, 2018

0

Why Illumina Might Be Offering a Lucrative Investment Opportunity

Illumina Showing 6% revenue increase over the same quarter last year, Q1 2016, was not enough as  Illumina (ILMN)  missed analysts’ expectations and its own projections regarding its revenues. Prior to the announcement of its Q1 results, the giant gene sequencing...

Read More

April 21, 2016

0

Vertex: A Cystic Fibrosis Institution with a Bright Future

Yesterday, Wednesday July 19, Vertex’s (VRTX) stock added over 20% to its value, recording a new all time high. Why? On Tuesday the firm announced a better than technical analysts’ and its own expectations’ results in three trials testing its...

Read More

July 20, 2017

0

Heron Therapeutics’ Product HTX-011: Helping in the War Against Opioids. Why Regeneron Could Fiercely Rebound

What Do We Make of the Following Good News? HERON THERAPEUTICS Will HTX-011 Help in the War Against Opioids?  Heron Therapeutics (HRTX) , a commercial-stage biotechnology company announced positive results from its completed Phase 3 studies of the investigational agent ...

Read More

March 20, 2018

0

Good News Does Not Always Mean Good Investment Opportunities

In the biotech sector, daily stories (news) are not just announced, but mostly edited in ways that project the narrators’ tendencies and wishes rather than the original news. Last week’s headlines comprised positive news from a firm’s drug aimed at...

Read More

April 18, 2016

0

Theravance Biopharma Has Good News for COPD Patients

Theravance Biopharma (TBPH) and Mylan N.V. (MYL) announced positive results from a 12-month Phase 3 safety study of revefenacin (TD-4208). The drug is an investigational long-acting muscarinic antagonist (LAMA) - a proposed once-daily, NEBULIZED bronchodilator for chronic obstructive pulmonary disease...

Read More

July 21, 2017

0

  • Previous
  • 1
  • 2
  • ...
  • 29
  • 30
  • 31
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy